Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lipella Pharmaceuticals, Inc. ( (LIPO) ) has issued an announcement.
On June 20, 2025, Lipella Pharmaceuticals announced that its common stock was delisted from the Nasdaq Capital Market due to non-compliance with certain Nasdaq listing rules related to shareholder approval and voting rights. The delisting follows private placement transactions that took place between December 2024 and March 2025. Despite the setback, Lipella remains operationally sound and is exploring other markets to list its stock while continuing its strategic and clinical development plans.
The most recent analyst rating on (LIPO) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Lipella Pharmaceuticals, Inc. stock, see the LIPO Stock Forecast page.
More about Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs. The company specializes in reformulating active agents in existing generic drugs to optimize them for new applications. Lipella targets diseases where no approved drug therapies currently exist.
Average Trading Volume: 80,593
Technical Sentiment Signal: Sell
Current Market Cap: $10.54M
See more data about LIPO stock on TipRanks’ Stock Analysis page.